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Introduction
Uridine and cytidine are substances belonging to the pyrimidine nucleotide family,
which in turn comprises one of four main classes of biological molecules (along
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Context: This paper reports on the results of treatment of compressive neuralgia using a
combination of nucleotides (uridine triphosphate trisodium [UTP] and cytidine monophosphate
disodium [CMP]) and vitamin B12.
Objectives: To assess the safety and efficacy of the combination of nucleotides (UTP and
CMP) and vitamin B12 in patients presenting with neuralgia arising from neural compression
associated with degenerative orthopedic alterations and trauma, and to compare these effects
with isolated administration of vitamin B12.
Methods: A randomized, double-blind, controlled trial, consisting of a 30-day oral treatment
period: Group A (n=200) receiving nucleotides + vitamin B12, and Group B (n=200) receiving
vitamin B12 alone. The primary study endpoint was the percentage of subjects presenting pain
visual analog scale (VAS) scores ≤20 at end of study treatment period. Secondary study endpoints
included the percentage of subjects presenting improvement ≥5 points on the patient functionality
questionnaire (PFQ); percentage of subjects presenting pain reduction (reduction in VAS scores
at study end in relation to pretreatment); and number of subjects presenting adverse events.
Results: The results of this study showed a more expressive improvement in efficacy evaluations
among subjects treated with the combination of nucleotides + vitamin B12, with a statistically
significant superiority of the combination in pain reduction (evidenced by VAS scores). There
were adverse events in both treatment groups, but these were transitory and no severe adverse
event was recorded during the study period. Safety parameters were maintained throughout the
study in both treatment groups.
Conclusion: The combination of uridine, cytidine, and vitamin B12 was safe and effective
in the treatment of neuralgias arising from neural compression associated with degenerative
orthopedic alterations and trauma.
Keywords: uridine triphosphate trisodium, cytidine monophosphate disodium, hydroxocobalamin, compressive neuralgia
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with carbohydrates, lipids, and proteins) that play several
fundamental roles in cellular metabolism. Aside from being
components of DNA and participating in genome transcription and translation, functions of these nucleotides include
energy transfer for chemical bonding, intracellular signaling,
neurotransmission, and transfer of biochemical radicals from
intermediate metabolism.1
Vitamin B12 is essential in the human body for growth
and maintenance of a variety of processes, including cell
reproduction and synthesis of myelin and nucleoproteins,
and must be supplied from an exogenous source.2 Adequate
vitamin B12 levels in the body depend on adequate ingestion
and absorption (requiring an acid-pepsin complex in the
stomach that releases cobalamin from its binding proteins,
pancreatic proteins that release cobalamin from the R factor
bond, secretion of intrinsic factor by gastric parietal cells
in order to bind cobalamin, and the presence of cobalamin
and intrinsic factor receptors in the ileum.3,4 Vitamin B12
is important to nerve metabolism via the remethylation
of homocysteine to methionine for de novo synthesis of
s-Adenosyl methionine.5 Vitamin B12 deficiency can be
caused by numerous factors, usually some combination of
inadequate ingestion and absorption.6 Deficiency can lead
to megaloblastic anemia and neurological alterations, the
latter likely linked to the absence of s-Adenosyl methionine
formation.7, 8
This trial assessed treatment outcomes following
administration of a combination of uridine triphosphate
trisodium (UTP), cytidine monophosphate disodium
(CMP), and vitamin B12 in the treatment of patients with
compressive neuralgias. There is a body of clinical and
preclinical evidence in the literature, supporting use of
CMP and UTP in neuropathic pain, with potential symptomatic benefits.9-22
Several preclinical studies of peripheral neuropathies
of varying etiologies have indicated beneficial effects
of UTP and CMP administration in situations such as
experimentally induced crush injury. Reported preclinical observations include accelerated nerve and muscle
fiber regeneration, increased nerve conduction velocity, increased levels of neuritic protein neurofilaments,
increased axon myelin surface area and thickness, and
increased levels of neuronal cell membrane phospholipids phosphatidylcholine and phosphatidylethanolamine
following nucleotide administration.19-22 In the clinical
setting, the combination of UTP and CMP with vitamin
B12 has been investigated in several painful conditions with
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favorable results, among which are diabetic neuropathy,
acute non-traumatic pain, lumbar pain, cervical pain, and
traumatic-compressive lesions.10-13, 18

Objectives
The objectives of this study were to assess the safety and
efficacy of the combination of nucleotides (UTP and CMP)
and vitamin B12 in patients presenting with neuralgia arising
from neural compression associated with degenerative orthopedic alterations and trauma, and to compare these effects
with isolated administration of vitamin B12.

Materials and methods
This was a randomized, double-blind, comparative, controlled trial performed at UNIFESO Medical School
facilities and hospital. The study was registered with the Brazilian National Database GGMED/GESF-ANVISA under
the following numbers: NOTIFICAÇÃO EM PESQUISA
CLÍNICA Nº 61/2014 Expediente do CE: 0331070141.
After study approval by the UNIFESO ethical committee
(approval no 509.682) and written informed consent of all
participants, subjects meeting inclusion criteria were randomized to a 30-day oral treatment period. Inclusion criteria
included patients of both genders, ≥18 years of age, with
a clinical presentation of degenerative orthopedic alteration with neural compression. Female patients performed a
urine pregnancy test prior to inclusion and were required to
maintain adequate birth control throughout the study period.
Exclusion criteria included need for surgical treatment and
need for other analgesics.
Enrolled subjects were randomized by order of arrival to
the study center into two treatment groups: Group A received
the combination of nucleotides and vitamin B12, while subjects in Group B received vitamin B12 monotherapy. The study
drug and treatment regimen was two capsules, three times
per day for Group A. Each capsule contained: CMP 2.5 mg;
UTP 1.5 mg; and hydroxocobalamin 1.0 mg. Study treatment
regimen for subjects in Group B was two capsules, three times
per day, each capsule contained hydroxocobalamin 1.0 mg.
There was no visible difference between the study drugs, in
accordance with blinding procedures for double-blind trials.
Subjects were instructed to swallow the capsules whole at
breakfast, lunch, and dinner.
The study hypothesis was that the combination of nucleotides and vitamin B12 would show superior efficacy in relation to B12 monotherapy. The study protocol outlined three
patient visits to the study center: pretreatment for screening,
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randomization, and study drug distribution; visit two took
place after 15 days of treatment; and visit three occurred at
the end of the 30-day treatment period. At each of these study
visits, subjects underwent a series of efficacy and tolerability
assessments.
Efficacy assessments included a 100 visual analog pain
scale (VAS), and the Patient Functionality Questionnaire
(PFQ), a 12-item yes or no questionnaire about management
of daily needs. The assessment included sleep quality, need
to rest, ability to get up, standing and climbing stairs, washing, drying, and dressing, picking up things from the floor,
changing posture, carrying weight, and need for assistance
from other people. At each assessment, the patient and the
investigating physician also evaluated the patient’s overall
condition on a scale of 1-10 points. Safety assessments
took into account vital signs at each assessment and occurrence, severity, and duration of any adverse effects, including
changes in laboratory tests.
The primary study endpoint was the percentage of
subjects presenting VAS ≤20 mm at end of study treatment
period. Secondary study endpoints included the percentage
of subjects presenting improvement ≥5 points on the PFQ;
percentage of subjects presenting pain reduction (reduction
in VAS scores at study end in relation to pretreatment); and
number of subjects presenting adverse events.
Study sample size took into account the results of a previous study,10 evaluating 80 subjects (40 per treatment group),
in which mean VAS scores at end of treatment were 21.11 in
the combination group versus 41.75 in the B12 monotherapy
group. Thus, a study sample size of 400 was determined,
taking into account the mean between group difference of
20.6mm and standard deviation of 10.3mm, from the previous study, with a standard error of 1.03. The 95% confidence
interval was 18.58–22.62, with a power of 1.0 and a twotailed alpha of 0.05. Data were statistically analyzed using
the software GraphPad Prism 5.0. Overall clinical efficacy
and tolerability were analyzed via comparison of the results
of each assessment in relation to pretreatment values, within
and between treatment groups. For categorical variables, we
used the χ2 or Fisher’s test, while continuous variables were
analyzed using the repeated measures ANOVA or Student’s
t-test.

Results
A total of 400 subjects were randomized to treatment, with
200 subjects per treatment group. Figure 1 shows the flow
of subjects through the trial. No significant between-group
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differences were noted at pretreatment in the demographic
data and pretreatment characteristics of the study population,
as summarized in Table 1.
The safety measures monitored during the study are summarized in Table 2. Pretreatment safety measures did not vary
significantly between Groups A and B: weight (p=0.148),
body mass index (BMI) (p=0.532), blood pressure (p=1.0
for systolic blood pressure and p=0.849 for diastolic blood
pressure), and heart rate (p=0.413). Throughout the treatment
period within the treatment groups, with the exception of
systolic blood pressure in both groups and diastolic blood
pressure in Group B, there was no statistically significant
change in weight (Group A, p=0.855; Group B, p =0.0603),
BMI (Group A, p =0.6; Group B, p =0.257), blood pressure
(Group A, p = 0.0013 for systolic blood pressure and p=0.133
for diastolic blood pressure; Group B, p =0.0046 for systolic
blood pressure and p=0.0032 for diastolic blood pressure),
and pulse (Group A, p=0.541; Group B, p=0.337).
Pretreatment PFQ scores were significantly lower among
patients in Group B (median for Group A, 9.0; median for
Group B, 8.0; p=0.0036). Median PFQ scores were 5.0 at visit
two in both treatment groups and 0.0 at visit three in both
treatment groups. Both groups showed statistically significant
improvement at the end of the study in relation to pretreatment PFQ scores (p<0.0001 for both treatment groups).
In relation to the secondary study endpoint, there was no
between-group difference in the percentage of subjects
presenting improvement ≥5 points on the PFQ (p=0.135).
Pretreatment patient overall assessment scores were
homogenous between treatment groups (p=0.29). At visits
two and three, the scores of this assessment improved within
each treatment group, but Group A patients showed a greater
improvement in scores at both visit two (p=0.014) and visit
three (p=0.0024) in comparison to Group B scores (Figure 2).
Physician overall assessment scores were also homogenous
between treatment groups at pretreatment (p=0.717), but
at visits two and three scores were significantly lower in
Group A as compared to Group B (p=0.0029 for visit two
and p=0.006 for visit three) (Figure 3).
At pretreatment, mean VAS scores among the patients in
Group A was 51.26mm (±12.38) while in Group B mean pretreatment VAS score was 51.06 (±11.72) (p=0.87). Visit two
VAS scores for Group A and Group B were 29.86 mm (±12.94)
and 33.88 mm (±11.86) (p=0.0014); At visit three, mean
Group A VAS scores were 16.06 mm (±12.03) and 20.40 mm
(±11.42) for Group B (p=0.0003). The percentage of subjects
presenting VAS scores ≤20 mm (primary study endpoint) at
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Pretreatment
Assessed for eligibility (n=741)

Excluded (n=341)
Not meeting inclusion criteria (n=341)
Refused to participate (n=0)
Other reasons (n=0)

Allocated to Group A (n=200)
Received allocated intervention (n=200)
Did not receive
allocated intervention (n=0)

Allocated to Group B (n=200)
Received allocated intervention (n=200)
Did not receive
allocated intervention (n=0)

Visit two
Lost to follow-up (n=1)
Noncompliance (n=2)
Concomitant Medication (n=2)
Continued treatment (n=195)

Visit two
Lost to follow-up (n=1)
Noncompliance (n=1)
Continued treatment (n=198)

Visit three
Patient relocated (n=1)
Withdrawn consent (improvment) (n=1)
Requested removal (improvement)
(n=1)
Treatment failure (n=1)

Visit three
Lost to follow-up (n=1)
Noncompliance (n=1)
Treatment failure (n=4)
Laboratory alteration (n=1)

Analyzed (n=191)
Excluded from analysis (n=0)

Analyzed (n=191)
Excluded from analysis (n=0)

Figure 1 Flowchart of subjects through the study

visit three was significantly higher in Group A as compared to
Group B (p=0.0425). Within the treatment groups, VAS score
reduction was statistically significant for both Group A and
Group B (p<0.0001 for both groups) (Figure 4).
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Adverse events were recorded in both treatment groups,
though for the most part these were not serious and were
transient. Table 3 summarizes the adverse events determined
by the investigating physician to be related to the study drug.
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Table 1 Pretreatment and demographic data

Table 2 Safety assessments

Variable

Parameters

Results
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Group A

Gender
Male
Female
Age (years)
Height (cm)
Ethnicity
Asian
Black
Caucasian
Mulatto
Pain location
Back pain
Hip pain
 Carpal tunnel
syndrome
Overall diet
Good
Moderate
Poor
Alcohol consumption
None
≤2 drinks/day
>2 drinks/day
Cigarette smoking
Non-smoker
<10 cigarettes/day
≥10 cigarettes/day
Manual labor
Light
Moderate
Heavy
Physical exercise
 Regular (at least
1×/week)
Irregular
None

Group B

Betweengroup
difference

Weight (kg)
Pretreatment
Visit two
Visit three
BMI
Pretreatment
Visit two
Visit three
Systolic blood pressure
(mmHg)
Pretreatment
Visit two
Visit three
Diastolic blood presssure
(mmHg)
Pretreatment
Visit two
Visit three
Pulse (bpm)
Pretreatment
Visit two
Visit three

p=0.6998
98
102
43.74 (±9.73)
166.91 (±9.23)

114
86
44.12 (±10.22)
168.49 (±8.86)

2
71
90
37

0
83
86
31

125
45
30

127
37
36

72
87
41

61
99
40

63
82
55

72
73
55

91
54
55

78
47
75

57
69
74

68
56
76

49

41

81
70

77
82

Results

p=0.133
p=0.0824
p=0.314

p=0.5112

p=0.415

p=0.57

Group A

Group B

72.27 (±12.29)
72.35 (±12.28
72.42 (±12.31)

74.05 (±12.27)
73.87 (±12.29)
74.04 (±12.39)

25.80 (±3.03)
25.80 (±3.013)
25.82 (±3.009)

25.99 (±3.05)
25.96 (±3.099)
26.02 (±3.121)

123.7 (±8.541)
122.4 (±7.376)
122.4 (±7.813)

123.7 (±7.285)
122.7 (±8.124)
123.0 (±7.644)

80.29 (±7.42)
79.67 (±7.755)
80.04 (±7.576)

80.14 (±8.269)
79.43 (±8.655)
79.38 (±8.672)

68.54 (±4.644)
68.17 (±5.165)
68.30 (±4.789)

68.92 (±4.503)
68.47 (±5.647)
68.57 (±4.648)

Notes: Data are n, or mean (±standard deviation). Group A: subjects treated with
uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.
Abbreviations: BMI, body mass index; bpm, beats per minute.

p=0.102

There was no between-group difference in the percentage
of subjects presenting adverse events during the treatment
period (p=0.6009).

p=0.309

Discussion
We report the results of a clinical trial using the combination
of uridine, cytidine, and vitamin B12 in the treatment of neuralgias caused by degenerative orthopedic alterations with neural
compression. This combination is commercially available in
Brazil under the brand name Etna®. The combination of the
nucleotides with vitamin B12 yielded a more significant pain

p=0.415

Notes: Data are n, or mean (±standard deviation). Group A: subjects treated with
uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.

100

Patients (n)

80
60
40

0

1

2

3

4

5

6

7

8

9

Pretreatment Group A

Pretreatment Group B

Visit two Group A

Visit two Group B

Visit three Group A

Visit three Group B

10

Figure 2 Patient overall assessment: graded on a 10 point scale from 1 (worst assessment of overall condition) to 10 (best assessment of overall condition) for treatment
groups A and B at each study visit.
Note: Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.
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100

Patients (n)

80
60
40

0

3

4

5

6

7

8

9

10

Pretreatment Group A

Pretreatment Group B

Visit two Group A

Visit two Group B

Visit three Group A

Visit three Group B

Table 3 Adverse events considered to be associated with study
drug administration

VAS
100

Adverse event

VAS (mm)

80
60
40
20

V3

G

ro

up

B/

V2
B/

up
ro
G

ro

up

B/

PT

V3
A/
G

up
ro
G

up
ro
G

ro

up

A/

A/

V2

PT

0

Treatment group / study visit
Figure 4 Visual analog scale scores for pain, for treatment groups A and B.
Note: Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B:
subjects treated with vitamin B12 alone.
Abbreviations: PT, pretreatment; VAS, visual analog scale; V2, visit two (after 15
days of treatment); V3, visit three (after 30 days of treatment).

reduction as measured by the VAS. Assessments performed
by both the patients and the investigating physician had higher
scores after 15 and 30 days of treatment among subjects treated
with the combination. Treatment with the combination and with
the control of vitamin B12 monotherapy resulted in significant
improvement in patient functionality throughout the treatment
period, as measured by the patient functionality questionnaire.
The findings of this study are in agreement with those
previously described in the literature. A previous study
performed by Goldberg et al (2009) assessed the use of this
combination in the treatment of back pain and hip pain,
reporting significant reduction in pain assessments as well
as functionality.10 As with the study of Goldberg and also
another recent study in alcoholic polyneuropathy in which the
authors compared the use of the combination of UTP + CMP
+ vitamin B12 with the use of vitamin B12 monotherapy,17 there
402
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Figure 3 Physician overall assessment: graded on a 10 point scale from 1 (worst assessment of overall condition) to 10 (best assessment of overall condition) for treatment
groups A and B at each study visit.
Note: Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.
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Group A
Abdominal colic
Abdominal discomfort
Abdominal distension
Abdominal distension
Abdominal disturbance
Feeling of bloating
Flatulence
Increased appetite
Nausea
Nausea
Group B
Abdominal discomfort
Abdominal distension
Abdominal distension
Constipation
Constipation
Elevated uric acid
Epigastralgia
Epigastralgia
Flatulence
Nausea
Nausea

Severity

Number
of affected
subjects

Mild
Moderate
Moderate
Mild
Moderate
Moderate
Moderate
Mild
Moderate
Mild

1
1
2
1
1
1
1
1
1
3

Mild
Moderate
Mild
Moderate
Mild
Mild
Mild
Moderate
Mild
Moderate
Mild

1
1
1
1
1
2
2
1
1
1
1

Note: Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B:
subjects treated with vitamin B12 alone.

was a significant improvement over the treatment period in
pain manifestations as compared to the monotherapy group,
although the patients within the monotherapy group also displayed significant improvement throughout the treatment as
compared to pretreatment status. This finding and that of our
study highlights the importance the vitamin B12 component
in the treatment of these painful conditions.
A limitation of this study was the inclusion of three
distinct pain locations: lower back, hip, and carpal tunnel
Journal of Pain Research 2017:10
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syndrome which ultimately reduced the number of subjects
in each pain subcategory. Future studies should focus on a
single pain location in order achieve more specific results.
Nevertheless, we believe the results of this study are in concordance with findings in the literature and serve to contribute
to the growing body of evidence indicating the therapeutic
value of the combination of UTP,CMP and vitamin B12 for
the treatment of peripheral neuropathies. It is also important
to point out that unlike vitamin B12 (which has been confirmed
to exhibit antinociceptive effects in both animal and human
studies) the nucleotides do not have any direct role in antiinflammation or analgesia and thus the symptomatic improvements observed in our study and in previous studies are
suggestive of structural neuroregeneration by the nucleotides
as a mechanism of action.10, 11, 14, 15 Indeed, previous studies
on animal models give credence to this notion, with previous observations of the nucleotides playing a positive role in
axon and myelin sheaths of nerve and muscle fibers during
regeneration following experimentally-induced damage, in
addition to improved nerve fiber conduction velocity.19-21
A combination of uridine, folic acid, and vitamin B12 was
recently reported to be effective in the treatment of carpal
tunnel syndrome. Although in a small scale exploratory
trial of 48 subjects, authors reported reduced pain scores
and improvement in symptom intensity following 60 days
of treatment with the combination therapy.23 An important
limiting factor in our study with regards to carpal tunnel
syndrome is the relatively small sample size in relation to
the total patient population, as mentioned in the preceding
paragraph. However, these findings together with the results
of our study warrant further investigation into the use of the
nucleotides and vitamin B12 in the treatment of this very
common ailment.
Clinical trials of painful conditions attributable to neuropathic pain (pain following neurological surgical procedures,
neural compression-induced neuralgias, chronic neuropathic
lumbar pain, peripheral neuropathies, and pain and paresthesia
related to B12 deficiency anemia) have consistently yielded
encouraging results with use of the combination of uridine,
cytidine, and vitamin B12, and further studies may reveal
additional indications where this combination or others like
it may be of use, while also expanding our understanding of
the interaction between the nucleotides and vitamin B12 in
painful conditions.9-21 For instance, the combination of uridine,
folic acid, and vitamin B12 was also reported to be effective in
neuropathic pain of peripheral neuropathies, with a reduction
in pain intensity and also allowing for reduction in concomitant medication use.23,24 These types of study are important
to explore new alternatives for addressing neuropathic pain
Journal of Pain Research 2017:10
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– with the aim of providing treatment options that reduce
pain, decreased need for other drugs with more unwanted side
effects, and improve patient care and quality of life.

Conclusion
The results of this study showed a more expressive improvement in efficacy evaluations among subjects treated with the
combination of nucleotides + vitamin B12, with a statistically
significant superiority of the combination in pain reduction
(evidenced by VAS scores). There were adverse events in
both treatment groups, but these were transitory and no
severe adverse event was recorded during the study period.
Safety parameters were maintained throughout the study in
both treatment groups. The combination of uridine, cytidine,
and vitamin B12 was safe and effective in the treatment of
neuralgias arising from neural compression associated with
degenerative orthopedic alterations and trauma. Considering these results, a prospective, multi-center randomized
controlled clinical trial, comparing the activity of vitamin
B12 alone to the activity of vitamin B12 in combination with
nucleotides in pain reduction, is warranted.
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